​

Alkermes (ALKS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALKS Stock Forecast

Alkermes (ALKS) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $37.67, with a high of $40.00 and a low of $36.00. This represents a 39.52% increase from the last price of $27.00.

$20 $24 $28 $32 $36 $40 High: $40 Avg: $37.67 Low: $36 Last Closed Price: $27

ALKS Stock Rating

Alkermes stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (47.62%), 10 Hold (47.62%), 1 Sell (4.76%), and 0 Strong Sell (0.00%).

Buy
Total 21 1 10 10 0 Strong Sell Sell Hold Buy Strong Buy

ALKS Price Target Upside V Benchmarks

TypeNameUpside
StockAlkermes39.52%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$35.00
Last Closing Price$27.00$27.00$27.00
Upside/Downside--29.63%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25286--16
Mar, 252841-15
Feb, 252741-14
Jan, 252751-15
Dec, 242741-14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024David AmsellemPiper Sandler$37.00$31.2518.40%37.04%
Nov 13, 2024Vamil DivanMizuho Securities$40.00$26.0753.43%48.15%
Nov 04, 2024Paul MatteisStifel Nicolaus$36.00$26.5935.39%33.33%
Oct 24, 2024Paul MatteisStifel Nicolaus$25.00$26.85-6.89%-7.41%
Oct 14, 2024Douglas TsaoH.C. Wainwright$37.00$28.9127.98%37.04%
Apr 10, 2024Akash TewariJefferies$25.00$13.3786.99%-7.41%
Apr 09, 2024Vamil DivanMizuho Securities$35.00$26.7330.94%29.63%
Apr 09, 2024Akash TewariJefferies$25.00$26.95-7.24%-7.41%
Mar 18, 2024Joel BeattyRobert W. Baird$37.00$27.5334.40%37.04%
Dec 06, 2022J.P. Morgan$29.00$25.0115.95%7.41%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 27, 2025Deutsche BankBuyBuyhold
Mar 04, 2025UBSBuyNeutralupgrade
Oct 14, 2024H.C. WainwrightNeutralNeutralhold
Oct 14, 2024H.C. WainwrightBuyBuyhold
Oct 10, 2024Cantor FitzgeraldUnderperformUnderperformhold
Sep 23, 2024JefferiesBuyBuyhold
Jul 25, 2024H.C. WainwrightNeutralNeutralhold
Jul 15, 2024H.C. WainwrightBuyBuyhold
Jun 17, 2024Piper SandlerBuyBuyhold
Jun 17, 2024Cowen & Co.Buyinitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.70$-0.30$-0.97$2.14$2.22----
Avg Forecast$0.36$0.58$0.23$1.60$2.62$1.74$1.97$1.68$1.80
High Forecast$0.37$0.61$0.24$1.79$2.80$1.98$2.76$2.60$1.88
Low Forecast$0.35$0.57$0.22$1.51$2.39$1.23$0.34$0.49$1.68
Surprise %-294.44%-151.72%-521.74%33.75%-15.27%----

Revenue Forecast

$1B $1B $1B $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.04B$1.17B$1.11B$1.66B$1.56B----
Avg Forecast$1.03B$1.16B$1.10B$1.65B$1.51B$1.41B$1.46B$1.43B$1.47B
High Forecast$1.06B$1.20B$1.13B$1.67B$1.52B$1.46B$1.47B$1.43B$1.52B
Low Forecast$1.00B$1.13B$1.05B$1.62B$1.48B$1.35B$1.45B$1.42B$1.39B
Surprise %1.15%1.35%1.37%0.85%3.27%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-110.86M$-48.17M$-158.27M$355.76M$367.07M----
Avg Forecast$60.53M$-151.10M$-447.50M$519.16M$441.17M$272.37M$211.64M$210.29M$304.67M
High Forecast$63.35M$-111.66M$-355.81M$625.33M$476.00M$336.78M$469.15M$441.92M$319.43M
Low Forecast$58.60M$-190.54M$-539.19M$412.99M$406.34M$207.96M$57.12M$83.33M$285.39M
Surprise %-283.15%-68.12%-64.63%-31.47%-16.80%----

ALKS Forecast FAQ

Is Alkermes stock a buy?

Alkermes stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Alkermes is a favorable investment for most analysts.

What is Alkermes's price target?

Alkermes's price target, set by 21 Wall Street analysts, averages $37.67 over the next 12 months. The price target range spans from $36 at the low end to $40 at the high end, suggesting a potential 39.52% change from the previous closing price of $27.

How does Alkermes stock forecast compare to its benchmarks?

Alkermes's stock forecast shows a 39.52% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Alkermes over the past three months?

  • April 2025: 12.50% Strong Buy, 50.00% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 13.33% Strong Buy, 53.33% Buy, 26.67% Hold, 6.67% Sell, 0% Strong Sell.
  • February 2025: 14.29% Strong Buy, 50.00% Buy, 28.57% Hold, 7.14% Sell, 0% Strong Sell.

What is Alkermes’s EPS forecast?

Alkermes's average annual EPS forecast for its fiscal year ending in December 2025 is $1.74, marking a -21.62% decrease from the reported $2.22 in 2024. Estimates for the following years are $1.97 in 2026, $1.68 in 2027, and $1.8 in 2028.

What is Alkermes’s revenue forecast?

Alkermes's average annual revenue forecast for its fiscal year ending in December 2025 is $1.41B, reflecting a -9.71% decrease from the reported $1.56B in 2024. The forecast for 2026 is $1.46B, followed by $1.43B for 2027, and $1.47B for 2028.

What is Alkermes’s net income forecast?

Alkermes's net income forecast for the fiscal year ending in December 2025 stands at $272.37M, representing a -25.80% decrease from the reported $367.07M in 2024. Projections indicate $211.64M in 2026, $210.29M in 2027, and $304.67M in 2028.